Literature DB >> 15872051

Arylamine N-acetyltransferase 2 expression in the developing heart.

Larissa Wakefield1, Valerie Cornish, Fiona Broackes-Carter, Edith Sim.   

Abstract

Murine arylamine N-acetyltransferase 2 (NAT2) is expressed in the developing heart and in the neural tube at the time of closure. Classically described as a xenobiotic metabolizing enzyme, there is increasing evidence for a distinct biological role for murine NAT2. We have characterized the expression of arylamine N-acetyltransferase 2 during cardiogenesis, mapping its expression in vivo, using a lacZ insertion deletion, and also in vitro, by measuring NAT2 enzyme activity. These findings show that cardiac Nat2 expression is both temporally and spatially regulated during development. In neonatal mice, cardiac Nat2 expression is most extensive in the central fibrous body and is evident in the atrioventricular valves and the valves of the great vessels. Whereas Nat2 expression is not detected in ventricular myocardial cells, Nat2 is strongly expressed in scattered cells in the region of the sinus node, the epicardium of the right atrial appendage, and in the pulmonary artery. Expression of active NAT2 protein is maximal when the developing heart attains the adult circulation pattern and moves from metabolizing glucose to fatty acids. NAT2 acetylating activity in cardiac tissue from Nat2(-/-) and Nat2(+/-) mice indicates a lack of compensating acetylating activity either from other acetylating enzymes or by NAT2 encoded by the wild-type Nat2 allele in Nat2(+/-) heterozygotes. The temporal and spatial control of murine Nat2 expression points to an endogenous role distinct from xenobiotic metabolism and indicates that Nat2 expression may be useful as a marker in cardiac development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15872051     DOI: 10.1369/jhc.4A6496.2005

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  6 in total

1.  Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1.

Authors:  David F Barker; Anwar Husain; Jason R Neale; Benjamin D Martini; Xiaoyan Zhang; Mark A Doll; J Christopher States; David W Hein
Journal:  Pharmacogenet Genomics       Date:  2006-07       Impact factor: 2.089

2.  Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene.

Authors:  Larissa Wakefield; Hilary Long; Nathan Lack; Edith Sim
Journal:  Mamm Genome       Date:  2007-05-09       Impact factor: 2.957

3.  Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-06-25       Impact factor: 3.922

4.  A follow-up study for left ventricular mass on chromosome 12p11 identifies potential candidate genes.

Authors:  David Della-Morte; Ashley Beecham; Tatjana Rundek; Liyong Wang; Mark S McClendon; Susan Slifer; Susan H Blanton; Marco R Di Tullio; Ralph L Sacco
Journal:  BMC Med Genet       Date:  2011-07-26       Impact factor: 2.103

5.  Mouse arylamine N-acetyltransferase 2 (Nat2) expression during embryogenesis: a potential marker for the developing neuroendocrine system.

Authors:  Larissa Wakefield; Valerie Cornish; Hilary Long; Akane Kawamura; Xiaoyan Zhang; David W Hein; Edith Sim
Journal:  Biomarkers       Date:  2008-02       Impact factor: 2.658

Review 6.  Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.

Authors:  E Sim; A Abuhammad; A Ryan
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.